ARS Pharmaceuticals (SPRY) News Today $12.57 +0.39 (+3.20%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by BrokeragesARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) has received an average rating of "Buy" from the six analysts that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the companyJanuary 17 at 2:33 AM | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Expected to Rise, Raymond James Analyst SaysJanuary 16 at 3:51 AM | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up Following Analyst UpgradeJanuary 16 at 1:59 AM | americanbankingnews.comAnalysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), ARS Pharmaceuticals (SPRY)January 15 at 10:01 AM | markets.businessinsider.comARS Pharmaceuticals price target raised to $28 from $26 at Raymond JamesJanuary 15 at 5:00 AM | markets.businessinsider.comRaymond James Sticks to Its Buy Rating for ARS Pharmaceuticals (SPRY)January 15 at 5:00 AM | markets.businessinsider.comRaymond James Forecasts Strong Price Appreciation for ARS Pharmaceuticals (NASDAQ:SPRY) StockRaymond James upped their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a research note on Tuesday.January 14, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up After Analyst UpgradeARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up Following Analyst UpgradeJanuary 14, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Expected to Rise, Leerink Partners Analyst SaysJanuary 14, 2025 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 7.6% After Analyst UpgradeJanuary 14, 2025 | americanbankingnews.comARS Pharmaceuticals shares surge on strong Q4 revenue for allergy sprayJanuary 13, 2025 | au.investing.comARS Pharmaceuticals reports preliminary Q4 neffy revenue $6.5MJanuary 13, 2025 | markets.businessinsider.comARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)January 13, 2025 | finance.yahoo.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 7.6% After Analyst UpgradeARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 7.6% After Analyst UpgradeJanuary 13, 2025 | marketbeat.comLeerink Partners Forecasts Strong Price Appreciation for ARS Pharmaceuticals (NASDAQ:SPRY) StockLeerink Partners upped their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an "outperform" rating in a report on Monday.January 13, 2025 | marketbeat.comBarclays PLC Has $1.62 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Barclays PLC raised its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 189.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 111,666 shares of the company's stock after purcJanuary 12, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,000 Shares of StockJanuary 8, 2025 | americanbankingnews.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells 50,000 Shares of StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) Director Laura Shawver sold 50,000 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $11.10, for a total value of $555,000.00. Following the sale, the director now owns 210,346 shares of the company's stock, valued at approximately $2,334,840.60. The trade was a 19.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.January 7, 2025 | marketbeat.comARS Pharmaceuticals files for approval of neffy in Canada, U.K.January 7, 2025 | finance.yahoo.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 2.8% - Here's WhyARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 2.8% - Time to Sell?January 6, 2025 | marketbeat.comARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/SJanuary 6, 2025 | globenewswire.comBarclays PLC Buys 73,127 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Barclays PLC boosted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 189.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 111,666 shares of the company's stock afterDecember 28, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 3.6% - Time to Sell?ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 3.6% - What's Next?December 26, 2024 | marketbeat.comInstitutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the greenDecember 24, 2024 | finance.yahoo.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Buy" by AnalystsARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) has earned an average rating of "Buy" from the six analysts that are presently covering the firm, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the companyDecember 23, 2024 | marketbeat.comState Street Corp Has $29.72 Million Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)State Street Corp grew its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 10.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 2,049,542 shares of the company's stock after acquiring an additional 193,321 shares during the peDecember 22, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 4% After Insider SellingARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 4% on Insider SellingDecember 20, 2024 | marketbeat.comARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National FormulariesDecember 19, 2024 | globenewswire.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 100,000 Shares of StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Sarina Tanimoto sold 100,000 shares of the company's stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $11.67, for a total value of $1,167,000.00. Following the sale, the insider now owns 1,098,499 shares in the company, valued at approximately $12,819,483.33. This trade represents a 8.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.December 19, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up - Here's What HappenedARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up - Still a Buy?December 19, 2024 | marketbeat.comFranklin Resources Inc. Reduces Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Franklin Resources Inc. cut its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 3.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,837,252 shares of the company's stock after sellDecember 18, 2024 | marketbeat.comBrian Dorsey Sells 25,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockDecember 14, 2024 | insidertrades.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 766.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fundDecember 14, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) COO Brian Dorsey Sells 25,000 SharesARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) COO Brian Dorsey sold 25,000 shares of ARS Pharmaceuticals stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $12.30, for a total transaction of $307,500.00. Following the sale, the chief operating officer now owns 6,024 shares in the company, valued at $74,095.20. This represents a 80.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.December 13, 2024 | marketbeat.comJustin Chakma Sells 27,272 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Justin Chakma sold 27,272 shares of the company's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $12.06, for a total transaction of $328,900.32. Following the sale, the insider now directly owns 136,380 shares in the company, valued at $1,644,742.80. This trade represents a 16.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.December 13, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.5% - Time to Sell?ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 5.5% - Should You Sell?December 13, 2024 | marketbeat.comARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and AustraliaDecember 12, 2024 | globenewswire.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sarina Tanimoto Sells 100,000 SharesDecember 12, 2024 | insidertrades.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Justin Chakma Sells 50,000 SharesARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Justin Chakma sold 50,000 shares of the firm's stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $14.23, for a total value of $711,500.00. Following the sale, the insider now owns 136,380 shares of the company's stock, valued at $1,940,687.40. The trade was a 26.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.December 6, 2024 | marketbeat.comCantor Fitzgerald Analysts Lower Earnings Estimates for SPRYARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share estimates for ARS Pharmaceuticals in a research report issued on Wednesday, December 4th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the companyDecember 6, 2024 | marketbeat.comWexford Capital LP Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Wexford Capital LP acquired a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 248,347 shares of the company's stock, valued at approximately $3,601,000. WDecember 6, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Buys 288,021 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Jacobs Levy Equity Management Inc. grew its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 78.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 653,048 shares of the company's stock after purcDecember 6, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $203,115.00 in StockDecember 5, 2024 | insidertrades.comARS Pharmaceuticals announces planned launch of neffyinSchoolsDecember 5, 2024 | markets.businessinsider.comARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No CostDecember 4, 2024 | globenewswire.comMiura Global Management LLC Takes $3.92 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Miura Global Management LLC bought a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 270,000 shares of the company's stock, valued atDecember 4, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $359,750.00 in StockNovember 28, 2024 | insidertrades.comConnor Clark & Lunn Investment Management Ltd. Purchases Shares of 77,208 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Connor Clark & Lunn Investment Management Ltd. purchased a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 77,208 shares of the company's sNovember 28, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Buy" from AnalystsARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) has been given an average recommendation of "Buy" by the six research firms that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating onNovember 28, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Rating of "Buy" by AnalystsShares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have received a consensus recommendation of "Buy" from the six research firms that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a buy rating and two have issued a strong buy ratiNovember 28, 2024 | marketbeat.com Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRY Media Mentions By Week SPRY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRY News Sentiment▼0.600.64▲Average Medical News Sentiment SPRY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRY Articles This Week▼185▲SPRY Articles Average Week Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VKTX News Today AXSM News Today TGTX News Today KRYS News Today ADMA News Today SRRK News Today ALVO News Today OGN News Today RARE News Today VRNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRY) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
